Back to Search
Start Over
Treatment approaches in relapsed or refractory peripheral T-cell lymphomas
- Source :
- F1000Research
- Publication Year :
- 2020
- Publisher :
- F1000 Research Ltd, 2020.
-
Abstract
- Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare and aggressive non-Hodgkin’s lymphomas. Clinical staging, prognostic scoring, and initial treatment strategies have historically been based on paradigms developed in B-cell lymphomas. Despite primary treatment protocols that are typically anthracycline-based and frequently involve consolidative autologous stem cell transplantation in first remission, many patients develop disease progression. There remains a high unmet medical need for improved treatment strategies in the relapsed or refractory setting. Salvage chemotherapy and stem cell transplantation in those who are suitable has traditionally been the accepted approach, but this remains a minority of the total patient population. As increasing knowledge is gleaned regarding the biological heterogeneity within the various PTCL subtypes, newer targeted agents have been developed, studied, and approved in this small, heterogeneous population of relapsed or refractory disease. Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL. As others undergo further development in the relapsed setting and successes are brought earlier in the disease course, the outcome for PTCL patients is likely to improve. However, innovative clinical trial designs are crucial for the assessment of targeted agents in this highly heterogeneous population. This review explores the current treatment environment for patients with relapsed and refractory PTCL, including newer strategies such as targeted agents and immunotherapy.
- Subjects :
- Oncology
medicine.medical_specialty
Antibody-drug conjugate
targeted agents
Population
Review
Transplantation, Autologous
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
0302 clinical medicine
Autologous stem-cell transplantation
Internal medicine
stem cell transplant
Humans
Medicine
T-cell lymphoma
General Pharmacology, Toxicology and Pharmaceutics
Brentuximab vedotin
education
Salvage Therapy
education.field_of_study
General Immunology and Microbiology
business.industry
Hematopoietic Stem Cell Transplantation
Lymphoma, T-Cell, Peripheral
Articles
General Medicine
Prognosis
medicine.disease
relapsed
Transplantation
Clinical trial
refractory
Tolerability
030220 oncology & carcinogenesis
Immunotherapy
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 20461402
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- F1000Research
- Accession number :
- edsair.doi.dedup.....a556aa0a38f46a8978006c477ed628a2